Skip to main content Back to Top


Fentanyl Transdermal System

Products Affected - Description

    • Fentanyl transdermal system, Alvogen, 100 mcg/hour, 5 count, NDC 47781-0428-47
    • Fentanyl transdermal system, Alvogen, 12.5 mcg/hour, 5 count, NDC 47781-0423-47
    • Fentanyl transdermal system, Alvogen, 25 mcg/hour, 5 count, NDC 47781-0424-47
    • Fentanyl transdermal system, Alvogen, 50 mcg/hour, 5 count, NDC 47781-0426-47
    • Fentanyl transdermal system, Alvogen, 75 mcg/hour, 5 count, NDC 47781-0427-47

Reason for the Shortage

    • Alvogen could not be reached for updated information.
    • Mallinckrodt refuses to provide availability information.
    • Mylan has fentanyl transdermal patches available.

Available Products

    • Fentanyl transdermal system, Mylan (Viatris), 100 mcg/hour, 5 count, NDC 00378-9124-98
    • Fentanyl transdermal system, Mylan (Viatris), 12.5 mcg/hour, 5 count, NDC 00378-9119-98
    • Fentanyl transdermal system, Mylan (Viatris), 25 mcg/hour, 5 count, NDC 00378-9121-98
    • Fentanyl transdermal system, Mylan (Viatris), 37.5 mcg/hour, 5 count, NDC 00378-9125-98
    • Fentanyl transdermal system, Mylan (Viatris), 50 mcg/hour, 5 count, NDC 00378-9122-98
    • Fentanyl transdermal system, Mylan (Viatris), 62.5 mcg/hour, 5 count, NDC 00378-9126-98
    • Fentanyl transdermal system, Mylan (Viatris), 75 mcg/hour, 5 count, NDC 00378-9123-98
    • Fentanyl transdermal system, Mylan (Viatris), 87.5 mcg/hour, 5 count, NDC 00378-9127-98

Estimated Resupply Dates

    • Alvogen has fentanyl 25 mcg/hour transdermal patches on back order and the company estimates a release date in late-June 2024. All other presentations are on allocation.


Updated April 14, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created May 1, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.